Should You Buy Neumora Therapeutics, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Neumora Therapeutics, Inc. (NMRA) scores 4.6/10 on our Quality of Company framework, indicating mixed operational fundamentals. At the current price of $0.83, our multi-model valuation analyzes whether the market has already discounted these weaknesses.
The short answer: 1 of 2 CirclFi valuation models project upside for Neumora Therapeutics, Inc. (NMRA) at $0.83 — the models are evenly split, with a Quality Score of 4.6/10 and Value-Trap risk of 42/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Neumora Therapeutics, Inc. (NMRA) in 2026?
What Is the Bull Case vs the Bear Case for Neumora Therapeutics, Inc. (NMRA)?
| Bull case — $0.93 target (+11.3%) | Bear case — $0.50 target (-39.9%) |
|---|---|
| Industry tailwind: breakthrough therapy designations could provide meaningful support for Neumora Therapeutics, Inc.'s revenue and margin trajectory in the Biotechnology space. | According to the CirclFi Quality of Company (QOC) framework, Neumora Therapeutics, Inc.'s score of 4.6/10 signals fundamental weaknesses that could undermine the investment thesis. |
| According to the CirclFi Value Trap algorithm, the stock shows moderate caution signals, meaning investors should verify that apparent undervaluation isn't masking declining business quality. | |
| According to the CirclFi Deep Alpha Valuation Engine, the PWERM model sees the stock as overvalued with a fair value of $0.50 (-39.9%), suggesting that the market price embeds overly optimistic growth assumptions. | |
| According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +51.2% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. | |
| Industry headwind: reimbursement uncertainty represents a meaningful risk for Neumora Therapeutics, Inc. and its Biotechnology peers. |
How Does NMRA Compare to Its Biotechnology Peers?
Valuation data pages: ACXP · AXIM · NTHI · BMEA · CNTX · SNTI · CERO · KYMR · EVFM · EXEL · INCY
Which Other Stocks Score Like NMRA on Quality?
Closest companies to NMRA’s Quality of Company score of 4.6/10, across all industries.
- FINS — Angel Oak Financial Strategies Income Term Trust (QOC 4.6) · analysis
- RMSL — REMSleep Holdings, Inc. (QOC 4.6) · analysis
- RITE — MineralRite Corporation (QOC 4.6) · analysis
- EURK — Eureka Acquisition Corp (QOC 4.6) · analysis
- VLT — Invesco High Income Trust II (QOC 4.6) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Biotechnology Screens Does NMRA Appear In?
So Is Neumora Therapeutics, Inc. (NMRA) Worth Buying in 2026?
Neumora Therapeutics, Inc. at $0.83 is a genuine coin-flip in our framework. The 1–1 bull-bear split across 2 models, +51.2% model spread, and median fair value of $0.71 (-14.3% vs price) argue for a watchlist position rather than a high-conviction bet. Quality at 4.6/10 adds additional caution to the mix.
These are quantitative model outputs, not investment recommendations. Neumora Therapeutics, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About NMRA Stock?
Should I buy NMRA stock right now?
Based on CirclFi's multi-model analysis, 1 of 2 models see upside for NMRA at $0.83. The models are divided, which means the investment case depends heavily on your assumptions about Neumora Therapeutics, Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Neumora Therapeutics, Inc.?
Key risks include: an elevated Value Trap score of 42/100, suggesting apparent undervaluation may mask deteriorating fundamentals; a below-average Quality Score of 4.6/10, indicating fundamental weakness; limited model coverage (2/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does NMRA compare to its competitors?
Among Biotechnology peers, NMRA holds a Quality Score of 4.6/10. Comparable companies include ACXP (QOC 4.6), AXIM (QOC 4.6), NTHI (QOC 4.6). The relative ranking helps investors identify whether NMRA offers better fundamental quality than alternatives in the same sector.
Is NMRA a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. NMRA's Quality Score of 4.6/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.
What price should I buy NMRA at?
CirclFi does not provide target buy prices or price alerts. However, our 2 active models produce fair value estimates ranging from $0.50 to $0.93. At $0.83, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for NMRA.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad